Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer?

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 3, 2006, Pages 169-176

  Vesely, David L ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Congestive heart failure; Diuretics; Natriuretic peptides; Renal failure

Indexed keywords

8 BROMO CYCLIC GMP; ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CARDIAC NATRIURETIC PEPTIDE; CREATININE; DOPAMINE; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NESIRITIDE; PEPTIDE HORMONE; PLACEBO; SODIUM; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ARTERY DILATATION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURGERY; CARCINOMA; CARCINOMA CELL; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIURETIC ACTIVITY; DOG; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG POTENCY; DRUG TREATMENT FAILURE; EXPERIMENTAL ANIMAL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FOOD AND DRUG ADMINISTRATION; HEART; HEART HEMODYNAMICS; HEART INDEX; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INOTROPISM; KIDNEY BLOOD FLOW; KIDNEY DISTAL TUBULE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; LOW DRUG DOSE; LUNG CAPILLARY PRESSURE; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG VASCULAR RESISTANCE; MARKETING; MORTALITY; NATRIURESIS; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PROGNOSIS; PROSTATE ADENOCARCINOMA; RISK ASSESSMENT; SEIZURE; SHORT SURVEY; SODIUM EXCRETION; SODIUM RETENTION; SODIUM URINE LEVEL; STATISTICAL SIGNIFICANCE; SYSTEMIC VASCULAR RESISTANCE; TERTIARY HEALTH CARE; TREATMENT DURATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; URINE FLOW RATE; URINE VOLUME; WATER RETENTION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NEOPLASMS;

EID: 33645086374     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04344.x     Document Type: Short Survey

References (72)

1. Gardner DG Kovacic-Milivojevic BK Garmai M Molecular biology of the natriuretic peptides In Vesely DL (ed.) Atrial Natriuretic Peptides Research Signpost Trivandrum, India 1997 15 38
2. Vesely DL Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression IUBMB Life 2002 53 153 9
3. Vesely DL Natriuretic hormones In Alpern RJ Hebert SC (eds) The Kidney: Physiology and Pathophysiology 4th edn Elsevier/Academic Press San Diego, CA 2006 in press )
4. Vesely DL Norris JS Walters JM Jespersen RR Baeyens DA Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta BiochemBiophysResCommun 1987 148 1540 8
5. 2-terminus are natriuretic and/or kaliuretic AmJPhysiol 1990 258 F1401 8
6. 2 JClinInvest 1992 89 1411 17
7. Benjamin BA Peterson TV Effects of proANF (31-67) on sodium excretion in conscious monkeys AmJPhysiol 1995 269 R1351 5
8. + reabsorption by ANP 31-67 ClinExpPharmacolPhysiol 1995 22 121 4
9. Villarreal D Reams GP Taraben A Freeman RH Hemodynamic and renal effects of proANF 31-67 in hypertensive rats ProcSocExpBiolMed 1999 221 166 70
10. Dietz JR Scott DY Landon CS Nazian SJ Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion AmJPhysiol 2001 280 R1510 17
11. Vesely DL Douglass MA Dietz JR et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans Circulation 1994 90 1129 40
12. Vesely DL Douglass MA Dietz JR et al. Negative feedback of atrial natriuretic peptides JClinEndocrinolMetab 1994 78 1128 34
13. Vesely DL Dietz JR Parks JR et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure Circulation 1998 98 323 9
14. Vesely DL Atrial Natriuretic Hormones Prentice Hall Englewood Cliffs, NJ 1992
15. Barr CS Rhodes P Struthers AD C-Type natriuretic peptide Peptides 1996 17 1243 51
16. Lainchbury J Richards AM Nicholls MG Brain natriuretic peptide in heart failure In Vesely DL (ed.) Atrial Natriuretic Peptides Research Signpost Trivandrum, India 1997 151 8
17. Vesely DL Natriuretic peptides and acute renal failure AmJPhysiol 2003 285 F167 77
18. Winters CJ Sallman AL Baker BJ Meadows J Rico DM Vesely DL The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure Circulation 1989 80 438 49
19. Vesely DL Norsk P Winters CJ Rico DM Sallman AL Epstein M Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans ProcSocExpBiolMed 1989 192 230 5
20. Hunter EFM Kelly PA Prowse C Woods FJ Lowry PJ Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease Scand. JClinLabInvest 1998 58 205 16
21. Franz M Woloszczuk W Horl WH N-Terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment Kidney Int 2000 58 374 8
22. De Palo EF Woloszczuk W Meneghetti M DePalo CB Nielsen HB Secher NH Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes ClinChem 2000 46 843 7
23. Franz M Woloszczuk W Horl WH Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases Kidney Int 2001 59 1928 34
24. Marcus LS Hart D Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusions in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial Circulation 1996 94 3184 9
25. Abraham WT Lowes BD Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure JCardiac Fail 1998 4 37 44
26. Jensen KT Eiskjaer H Carstens J Pedersen EB Renal effects of brain natriuretic peptide in patients with congestive heart failure ClinSci 1999 96 5 15
27. Mills RM LeJemtel TH Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial JAmCollCardiol 1999 34 155 62
28. Hoffman A Grossman E Keiser HR Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure AmJHypertens 1991 4 597 601
29. Sackner-Bernstein JD Skopicki HA Aaronson KD Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 2005 111 1487 91
30. Scios Inc. NDA 20-920: Cardiovascular and Renal Drugs Advisory Committee Briefing Document (3749b2_01_Sciospdf) 25 May 2001 Scios. Available on-line at. Accessed 25 August 2001
31. Cardiovascular and Renal Drugs Advisory Committee. Meeting Transcript 25 May 2002 3749t2.rtf. US FDA. Available on-line at. Accessed 28 September 2001
32. Karkowsky A 3749b2_02_02-FDA-Medical ReviewpdfNDA 20-92015 May 2001 US FDA. Available on-line at. Accessed 28 September 2001
33. Hung H Statistical review and evaluationNDA 20-920 Major Amendment (3749b2_02_04-FDA-Statistical-reviewpdf)April 2001 US FDA. Available on-line at. Accessed 28 September 2001
34. Medical Information Department SI. Preliminary Results from the Proaction Pilot Trail Scios Sunnyvale, CA
35. Scios Inc Natrecor Product Insert, Revised September 2001. Available on-line at. Accessed 25 August 2002
36. Scios Inc. NDA 20-920 Cardio-Renal Advisory Committee Briefing Document (3749B2_01_Scios-1999pdf), Last Updated 11 January 1999 Available on-line at. Accessed 25 August 2001
37. Smith GL Vaccarino V Kosiborod M et al. Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? JCardiacFail 2003 9 13 25
38. Gottlieb SS Abraham W Butler J et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure JCardiac Fail 2002 8 136 41
39. Krumholz HM Chen YT Vaccarino V et al. Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure AmJCardiol 2000 85 1110 13
40. Butler J Forman DE Abraham WT et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients AmHeart J 2004 147 331 8
41. Sackner-Bernstein JD Kowalski M Fox M Aaronson K Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials JAMA 2005 293 1900 5
42. Cataliotti A Schriger JA Martin FL et al. Orally available BNP: A newly developed conjugated form of human BNP lowers blood pressure and activates cGMP when administered orally in normal conscious dogs JAmCollCardiol 2005 45 (Suppl. A) 419A Abstract
43. Scriven TA Burnett Jr. JC Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure Circulation 1985 72 892 7
44. Cody RJ Atlas SA Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion JClinInvest 1986 78 1362 74
45. Freeman RH Davis JO Vari RC Renal response to atrial natriuretic factor in conscious dogs with caval constriction AmJPhysiol 1985 248 R495 500
46. Villarreal D Freeman RH Johnson RA Renal effects of ANF (95-126), a new atrial peptide analogue, in dogs with experimental heart failure AmJHypertens 1991 4 508 15
47. Vesely DL Dietz JR Parks JR et al. Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure AmHeart J 1999 138 625 32
48. Nasser A Dietz JR Siddique M et al. Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure AmJCardiol 2001 88 23 9
49. Woolf AS Mansell MA Hoffbrand BI Cohen SL Moult PJ The effect of low-dose intravenous 99-126 atrial natriuretic factor infusion in patients with chronic renal failure PostgradMedJ 1989 65 362 6
50. Hou SH Bushinsky DA Wish JB Cohen JJ Harrington JT Hospital-acquired renal insufficiency: A prospective study AmJMed 1983 74 243 8
51. Schafferhans K Heidbreder E Grimm D Heidland A Norepinephrine-induced acute renal failure: Beneficial effects of atrial natriuretic factor Nephron 1986 44 240 4
52. Rahman SN Kin GE Mathew AS et al. Effects of atrial natriuretic peptide in clinical acute renal failure Kidney Int 1994 45 1731 8
53. Con ger JD Falk SA Yuan BH Schrier RW Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure Kidney Int 1989 35 1126 32
54. Nakamoto M Shapiro JI Shanley PF Chan L Schrier RW In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure JClinInvest 1987 80 698 705
55. Shaw SG Weidmann P Hodler J Zimmermann A Paternostro A Atrial natriuretic peptide protects against ischemic renal failure in the rat JClinInvest 1987 80 1232 7
56. Neumayer HH Blossei N Seherr-Thohs U Wagner K Amelioration of postischaemic acute renal failure in conscious dogs by human atrial natriuretic peptide NephrolDialTransplant 1990 5 32 8
57. Allgren RL Marbury TC Rahman SN et al. Anaritide in acute tubular necrosis NEnglJMed 1997 336 828 34
58. Lewis J Salem MM Chertow GM et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group AmJKidney Dis 2000 36 767 74
59. Brenner RM Chertow GM The rise and fall of atrial natriuretic peptide for acute renal failure CurrOpinNephrolHypertens 1997 6 474 6
60. Kurnik BR Allgren RL Genter FC Solomon RJ Bates ER Weisberg LS Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy AmJKidney Dis 1998 31 674 80
61. Clark LC Farghaly H Saba SR Vesely DL Amelioration with vessel dilator of acute tubular necrosis and renal failure established for two days AmJPhysiol 2000 278 H1555 64
62. Vesely BA McAfee Q Gower Jr. WR Vesely DL Four peptides decrease the number of human pancreatic adenocarcinoma cells EurJClinInvest 2003 33 998 1005
63. Vesely DL Clark LC Garces AH McAfee QW Soto J Gower Jr. WR Novel therapeutic approach for cancer using four cardiovascular hormones EurJClinInvest 2004 34 674 82
64. Vesely BA Song S Sanchez-Ramos J et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells EurJClinInvest 2005 35 60 9
65. Vesely BA Fitz SR Gower Jr. WR et al. Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells Cancer Lett 2006 in press)
66. Vesely BA Song S Sanchez-Ramos J et al. Five cardiac hormones decrease the number of human small-cell lung cancer cells EurJClinInvest 2005 35 388 98
67. Wolff RA Abbruzzese JL Evans DB Neoplasms of the exocrine pancreas In Holland JF Frei III. E (eds) Cancer Medicine BC Decker
68. Saba SR Garces AH Clark LC et al. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas JHistochemCytochem 2005 53 989 95
69. Mohapatra SS Lockey RF Vesely DL Gower Jr. WR Natriuretic peptides and genesis of asthma: An emerging paradigm? JAllergy ClinImmunol 2004 114 520 6
70. Vesely BA Alli AA Song S Gower Jr. WR Sanchez-Ramos J Vesely DL Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur. J. Clin. Invest 2005 35 700 10
71. Gower Jr. WR Vesely BA Alli AA Vesely DL Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′,5′-cyclic monophosphate. Int. J. Gastrointest. Cancer 2006 in press )
72. Rashed HM Su H Patel TB Atrial natriuretic peptide inhibits growth of hepatoblastoma (HEP G2) cells by means of activation of clearance receptors Hepatology 1993 17 677 84